Anavex ‘Cautiously Optimistic’ After Noting Cognitive Improvement in Alzheimer’s Treatment

Anavex ‘Cautiously Optimistic’ After Noting Cognitive Improvement in Alzheimer’s Treatment
Anavex Life Sciences says its Alzheimer’s drug candidate Anavex 2-73 may have a role in treating the disease. Data from a long-term extension trial, although small, indicated that the therapy improved cognitive and functional measures in patients. According to data presented during the recent 10th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting in Boston, the most benefit was seen in early-stage patients treated with higher doses of the drug, which appeared safe across three studies. “We are cautiously optimistic about the promising results of Anavex 2-73 observed in patients who have received the drug for over two years,” Christopher Missling, president and CEO of New York-based Anavex,
Subscribe or to access all post and page content.

2 comments

  1. Robert Jacklin says:

    This is the first time I’ve ever read an article on a AD trial that over a 57 week trial a well tolerated oral drug has IMPROVED cognition! Looks like Anavex has discovered the right target.

  2. Doogie Howser says:

    Big Pharma and the Conservative Corporate Socialists are American’s problem, as to why no cures are being approved or accepted. The Medicine’s now are creating the symptoms while others given are creating the problem and last but not least, the smallest amount of improvement is a mask without any improvement to say the least.

Leave a Comment

Your email address will not be published. Required fields are marked *